Related Experiment Video
Updated: Oct 17, 2025
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
8.0K
Prognostic and Predictive Biomarkers in Gliomas
Paulina Śledzińska1,2, Marek G Bebyn2,3, Jacek Furtak4,5
1Department of Thoracic Surgery and Tumors, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, 85-067 Torun, Poland.
International Journal of Molecular Sciences
|October 13, 2021
Summary
New biomarkers like IDH mutations and H3F3A alterations are crucial for glioma prognosis and treatment. Liquid biopsies offer promising future diagnostic and predictive capabilities for brain tumors.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Genetics
Background:
- Gliomas are primary central nervous system tumors.
- Recent advancements in genetic research and statistical methods are transforming glioma treatment.
- The 2021 WHO Classification of CNS Tumors integrated molecular biomarkers, altering glioma classification.
Purpose of the Study:
- To review the latest research on prognostic and predictive biomarkers in gliomas.
- To highlight key molecular markers influencing glioma diagnosis, prognosis, and treatment response.
Main Methods:
- Literature review of recent studies on glioma biomarkers.
- Analysis of molecular alterations and their clinical significance.
- Discussion of emerging technologies like liquid biopsies.
Main Results:
- In adults, IDH mutations are key prognostic markers; CDKN2A deletion indicates high malignancy in IDH-mutant astrocytomas.
- TERT promoter mutations, EGFR alterations, or chr7 gain/chr10 loss define IDH-wildtype astrocytoma as glioblastoma.
- H3F3A alterations are critical prognostic markers in pediatric gliomas.
- MGMT promoter methylation predicts temozolomide (TMZ) response, while mismatch repair defects predict poor response to TMZ.
Conclusions:
- Molecular biomarkers significantly refine glioma classification and patient management.
- IDH, H3F3A, CDKN2A, TERT, EGFR, and MGMT status are critical for predicting glioma outcomes.
- Liquid biopsies show potential for glioma diagnostics and prognostics, requiring further clinical validation.
